AUROPHARMA.NSAUROPHARMA.NSNSE

Revenue (LTM)

$317.2B

+9.4% YoY

Net Income (LTM)

$34.9B

+9.9% YoY

Free Cash Flow

$19.6B

Revenue CAGR (5Y)

+6.6%

—Marginsstable

FCFTurned positive

Profitable

Metric	Mar 21	Mar 22	Mar 23	Mar 24	Mar 25
Revenue	247,746	234,555↓5.3%	248,554↑6.0%	290,019↑16.7%	317,237↑9.4%
Gross Profit	145,849	130,056↓10.8%	132,137↑1.6%	160,162↑21.2%	182,399↑13.9%
Operating Income	94,032	78,059↓17.0%	81,049↑3.8%	104,504↑28.9%	120,009↑14.8%
Net Income	53,348	26,482↓50.4%	19,275↓27.2%	31,730↑64.6%	34,859↑9.9%
EBITDA	53,947	43,114↓20.1%	36,344↓15.7%	57,641↑58.6%	64,364↑11.7%
EPS Diluted	91.05	45.19↓50.4%	32.90↓27.2%	54.15↑64.6%	59.81↑10.5%

Metric	Mar 21	Mar 22	Mar 23	Mar 24	Mar 25
Cash & Equivalents	53,735	41,625↓22.5%	43,963↑5.6%	33,935↓22.8%	82,355↑142.7%
Total Current Assets	198,235	181,227↓8.6%	215,457↑18.9%	242,056↑12.3%	271,625↑12.2%
Total Assets	338,540	339,217↑0.2%	398,900↑17.6%	450,715↑13.0%	497,850↑10.5%
Total Current Liabilities	106,651	81,560↓23.5%	114,938↑40.9%	121,991↑6.1%	146,823↑20.4%
Total Liabilities	119,250	93,477↓21.6%	130,381↑39.5%	152,207↑16.7%	171,380↑12.6%
Total Equity	219,299	245,760↑12.1%	268,399↑9.2%	298,428↑11.2%	326,533↑9.4%
Total Debt	53,391	32,790↓38.6%	52,862↑61.2%	66,476↑25.8%	82,629↑24.3%
Net Debt	-344	-8,836↓2469.2%	8,899↑200.7%	32,542↑265.7%	274↓99.2%

Metric	Mar 21	Mar 22	Mar 23	Mar 24	Mar 25
Operating Cash Flow	33,291	50,165↑50.7%	23,868↓52.4%	24,345↑2.0%	39,246↑61.2%
Capital Expenditure	-18,738	-27,046↓44.3%	-27,204↓0.6%	-35,615↓30.9%	-19,679↑44.7%
Free Cash Flow	14,552	23,118↑58.9%	-3,337↓114.4%	-11,270↓237.8%	19,568↑273.6%
Stock-Based Comp	86	0	0	89	0
Net Change in Cash	25,831	-11,674↓145.2%	2,298↑119.7%	-10,068↓538.2%	21,784↑316.4%

Values in millions except EPS · Ratios shown as percentages · Click any metric to drill down

Explore More

Filter and sort all 500 stocks

Today's biggest gainers and losers

Visual sector performance